Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 04:00PM ET
Dollar change
Percentage change
Index- P/E7.20 EPS (ttm)0.20 Insider Own6.17% Shs Outstand77.92M Perf Week9.92%
Market Cap112.20M Forward P/E- EPS next Y-0.55 Insider Trans-0.98% Shs Float73.11M Perf Month4.35%
Income16.53M PEG- EPS next Q-0.10 Inst Own66.10% Short Float11.01% Perf Quarter-22.58%
Sales119.18M P/S0.94 EPS this Y-1825.60% Inst Trans-17.91% Short Ratio1.15 Perf Half Y-13.51%
Book/sh-0.46 P/B- EPS next Y-184.32% ROA7.89% Short Interest8.05M Perf Year-22.99%
Cash/sh1.93 P/C0.75 EPS next 5Y-0.90% ROE- 52W Range1.04 - 5.85 Perf YTD-7.10%
Dividend Est.- P/FCF- EPS past 5Y67.21% ROI- 52W High-75.38% Beta1.10
Dividend TTM- Quick Ratio1.16 Sales past 5Y28.25% Gross Margin96.72% 52W Low38.46% ATR (14)0.12
Dividend Ex-Date- Current Ratio1.16 EPS Y/Y TTM122.25% Oper. Margin15.77% RSI (14)49.19 Volatility7.42% 7.38%
Employees122 Debt/Eq- Sales Y/Y TTM51.43% Profit Margin13.87% Recom2.00 Target Price5.32
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q433.80% Payout- Rel Volume0.07 Prev Close1.51
Sales Surprise114.28% EPS Surprise266.50% Sales Q/Q76.45% EarningsMay 08 AMC Avg Volume7.00M Price1.44
SMA209.09% SMA50-19.34% SMA200-14.87% Trades Volume456,507 Change-4.64%
Date Action Analyst Rating Change Price Target Change
May-28-24Upgrade Piper Sandler Neutral → Overweight $2.25 → $3.50
May-09-24Upgrade Wedbush Neutral → Outperform $8
May-06-24Upgrade Jefferies Hold → Buy $2.50 → $8
Apr-22-24Upgrade JP Morgan Underweight → Neutral
Nov-14-22Downgrade BMO Capital Markets Outperform → Market Perform $3 → $2.60
Jul-07-22Downgrade Wedbush Outperform → Neutral $6 → $2
Jul-07-22Downgrade Piper Sandler Overweight → Neutral $10 → $1.50
Jul-07-22Downgrade Mizuho Buy → Neutral $16 → $4
Jul-07-22Downgrade Jefferies Buy → Hold $12 → $2
Jun-24-22Initiated BMO Capital Markets Outperform $9
Jun-18-24 08:00AM
Jun-17-24 04:15PM
Jun-05-24 06:00AM
Jun-03-24 09:17AM
May-29-24 06:25AM
04:05PM Loading…
May-22-24 04:05PM
May-16-24 04:15PM
May-15-24 11:14AM
May-09-24 04:17PM
09:58PM Loading…
May-08-24 09:58PM
May-07-24 04:15PM
May-06-24 07:09AM
May-02-24 08:08AM
May-01-24 12:11PM
Apr-08-24 08:00AM
Apr-03-24 08:00AM
Mar-21-24 08:00AM
Mar-18-24 08:00AM
09:12AM Loading…
Mar-12-24 09:12AM
Mar-11-24 05:34PM
Mar-04-24 08:00AM
Feb-27-24 11:52AM
Jan-24-24 08:00AM
Jan-12-24 08:00AM
Jan-04-24 08:00AM
Dec-21-23 08:00AM
Nov-13-23 12:00PM
Nov-08-23 10:15AM
Nov-07-23 05:05PM
Nov-01-23 08:00AM
Oct-31-23 08:00AM
Oct-30-23 08:00AM
Oct-18-23 04:30PM
Sep-05-23 04:05PM
Aug-25-23 09:35AM
Aug-10-23 04:05PM
Aug-08-23 05:30PM
Aug-01-23 08:00AM
Jul-20-23 09:00AM
Jul-17-23 08:00AM
Jun-30-23 08:00AM
Jun-08-23 09:02AM
Jun-01-23 04:05PM
May-11-23 06:05AM
May-10-23 08:13AM
May-09-23 05:35PM
May-05-23 06:34AM
May-01-23 04:01PM
Apr-27-23 10:03AM
Apr-25-23 04:05PM
Mar-30-23 11:26AM
Mar-29-23 06:06AM
Mar-28-23 01:35PM
Mar-27-23 05:35PM
Mar-22-23 07:23PM
Mar-20-23 06:14AM
Feb-28-23 04:05PM
Feb-07-23 06:07AM
Jan-26-23 07:00AM
Jan-17-23 04:05PM
Jan-12-23 05:30AM
Jan-06-23 06:44PM
Jan-05-23 05:11PM
Dec-22-22 05:00PM
Dec-20-22 05:00PM
Dec-07-22 04:30PM
Nov-23-22 12:18PM
Nov-18-22 01:18PM
Nov-17-22 11:14AM
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCarthy Sean A.CEOMar 26 '24Option Exercise1.57109,768172,874634,249Mar 28 07:12 PM
McCarthy Sean A.CEOMar 19 '24Sale2.0920,22342,175524,481Mar 21 04:40 PM
BELVIN MARCIASVP, Chief Scientific OfficerMar 19 '24Sale2.0912,79526,684168,579Mar 21 04:37 PM
Landau Jeffrey BChief Business OfficerMar 19 '24Sale2.096,56213,685110,060Mar 21 04:36 PM
ROWLAND LLOYD AGeneral CounselMar 19 '24Sale2.095,26810,986117,728Mar 21 04:41 PM
Ogden ChristopherSVP, Finance and AccountingMar 19 '24Sale2.092,9716,19685,686Mar 21 04:38 PM
McCarthy Sean A.CEODec 20 '23Sale1.3813,55118,710454,704Dec 22 04:16 PM
ROWLAND LLOYD AGeneral CounselDec 20 '23Sale1.384,0775,62997,996Dec 22 04:11 PM
BELVIN MARCIASVP, Chief Scientific OfficerDec 20 '23Sale1.384,0775,628155,124Dec 22 04:14 PM
Landau Jeffrey BChief Business OfficerDec 20 '23Sale1.384,0775,62886,622Dec 22 04:12 PM
Ogden ChristopherSVP, Finance and AccountingDec 20 '23Sale1.381,9902,74748,657Dec 22 04:10 PM
Ogden ChristopherSVP, Finance and AccountingDec 17 '23Option Exercise0.006,875050,647Dec 19 07:58 PM
McCarthy Sean A.CEODec 17 '23Option Exercise0.0037,5000468,255Dec 19 07:57 PM
Landau Jeffrey BChief Business OfficerDec 17 '23Option Exercise0.0011,250090,699Dec 19 07:56 PM
ROWLAND LLOYD AGeneral CounselDec 17 '23Option Exercise0.0011,2500102,073Dec 19 07:55 PM
BELVIN MARCIASVP, Chief Scientific OfficerDec 17 '23Option Exercise0.0011,2500159,201Dec 19 07:54 PM
McCarthy Sean A.CEOSep 22 '23Sale1.3014,60118,987430,755Sep 22 07:13 PM
ROWLAND LLOYD AGeneral CounselSep 22 '23Sale1.305,4867,13580,609Sep 22 07:12 PM
BELVIN MARCIASVP, Chief Scientific OfficerSep 22 '23Sale1.304,1195,356147,951Sep 22 07:16 PM
Landau Jeffrey BChief Business OfficerSep 22 '23Sale1.304,1195,35676,379Sep 22 07:15 PM